id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-N-0129-0013,FDA,FDA-2012-N-0129,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; General Licensing
Provisions; Section 351(k) Biosimilar Applications",Notice,30 Day Proposed Information Collection,2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,2018-12-21T04:59:59Z,2018-11-20T14:24:41Z,2018-25232,0,0,09000064838ec50e
FDA-2012-N-0129-0012,FDA,FDA-2012-N-0129,Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions; Section 351(k) Biosimilar  Applications,Notice,60 Day Proposed Information Collection,2018-07-03T04:00:00Z,2018,7,2018-07-03T04:00:00Z,2018-09-05T03:59:59Z,2018-07-03T13:13:34Z,2018-14265,0,0,09000064834948fb